If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
In the late 1950s, he studied the role of enzymes in brain function, believing that mental illness may be partly caused by enzyme dysfunction. In the 1960s, as part of his interest in the effects of nuclear weapons, he investigated the role of mutations in evolution, proposing with his student Emile Zuckerkandl, the molecular evolutionary clock, the idea that mutations in proteins and DNA accumulate at a constant rate over time .
Bill Rosenberg opened the Open Kettle in 1948, a restaurant selling doughnuts and coffee in Quincy, Massachusetts (a suburb of Boston), but in late May 1950, he changed the name to Dunkin' Donuts after discussions with company executives. He conceived the idea for the restaurant after his experiences selling food in factories and at construction sites, where doughnuts and coffee were the two most popular items. The company introduced its first logo in 1953, and the mascot Dunkie in 1954. The restaurant was successful, and Rosenberg sold franchises to others starting in 1955. It was during this time that Johnny Spartos, one of the men running the original Quincy location, convinced Rosenberg to produce a donut with a handle specifically for dunking into a cup of coffee.
=== General uses === Banana powder has been found to be a "major source of carbohydrate and calories". While it is generally low as a source of protein, the beneficial ingredients of the powder are still "markedly superior to that of other fruits". The powder has also been found to be useful as a general treatment for dyspepsia (indigestion).
== Sources == Espy, Richard (1981). The Politics of the Olympic Games: With an Epilogue, 1976–1980. University of California Press. ISBN 9780520043954. Retrieved 16 June 2013. Honey, Andrew (2000). "South Africa and the Olympic Movement" (PDF). In K.B. Wamsley; S.G. Martyn; G. H. MacDonald; R.K. Barney (eds.). Bridging Three Centuries: Intellectual Crossroads and the Modern Olympic Movement. International Symposium for Olympic Research. pp. 177–184. Retrieved 17 June 2013. Killanin, Michael Morris, Lord (1983). "V: South Africa". My Olympic Years. New York: Morrow. pp. 33–45. ISBN 978-0-688-02209-9 – via Internet Archive. Ramsamy, Sam (1991). "Apartheid and Olympism: on the Abolishment of Institutionalized Discrimination in International Sport". In Fernand Landry; Marc Landry; Magdeleine Yerlès (eds.). Sport, the Third Millennium: Proceedings of the International Symposium, Quebec City, Canada, May 21-25, 1990. Presses Université Laval. pp. 539–548. ISBN 9782763772677. Retrieved 17 June 2013.
Sources: en.wikipedia.org
The application of nuclear magnetic resonance best known to the general public is magnetic resonance imaging for medical diagnosis and magnetic resonance microscopy in research settings. However, it is also widely used in biochemical studies, notably in NMR spectroscopy such as proton NMR, carbon-13 NMR, deuterium NMR and phosphorus-31 NMR. Biochemical information can also be obtained from living tissue (e.g. human brain tumors) with the technique known as in vivo magnetic resonance spectroscopy or chemical shift NMR microscopy. These spectroscopic studies are possible because nuclei are surrounded by orbiting electrons, which are charged particles that generate small, local magnetic fields that add to or subtract from the external magnetic field, and so will partially shield the nuclei. The amount of shielding depends on the exact local environment. For example, a hydrogen bonded to an oxygen will be shielded differently from a hydrogen bonded to a carbon atom. In addition, two hydrogen nuclei can interact via a process known as spin–spin coupling, if they are on the same molecule, which will split the lines of the spectra in a recognizable way. As one of the two major spectroscopic techniques used in metabolomics, NMR is used to generate metabolic fingerprints from biological fluids to obtain information about disease states or toxic insults.
=== Excretion === The elimination of 2,6-DCBQ and its derivatives occurs predominantly through the renal system. Due to its high reactivity, levels of the unchanged parent compound are negligible. Instead, the compound is excreted in the form of water-soluble metabolites, specifically mercapturic acid derivatives. Biliary excretion is a secondary possibility, but urinary elimination remains the dominant pathway for the clearance of 2,6-DCBQ metabolites from the body.
Rats that were fed a standard diet showed a progressive degradation of myelin, on day 14 post DAI it was evident that myelin sheaths have collapsed, dissolved or disappeared from the injured axons. For the axons with remaining myelin, the myelin was becoming thinner. Rats that were served ketogenic diets presented axons with thicker myelin in comparison to the standard diet rats. The marker that was used to determine axonal injury in this study was amyloid precursor protein (APP). Rats that were fed a standard diet and an uptake of APP, leading to an increase in damaged/injured axons.
As a member of Team X, Logan was given false memory implants. Eventually breaking free of this mental control, he joined the Canadian Defense Ministry. Logan was subsequently kidnapped by the Weapon X program, where he was held captive and made a subject of experiments; the program fused adamantium onto his bones, before he escaped. James and Heather Hudson helped him recover his humanity following his escape, and Logan began work as an intelligence operative for the Canadian government's Department H. He becomes Wolverine, one of Canada's first superheroes. In his first mission, he is dispatched to stop the destruction caused by a brawl between the Hulk and the Wendigo. Professor Charles Xavier recruits Wolverine to a new iteration of his superhero-mutant team, the X-Men. He competes with Cyclops for the affection of Jean Grey. While his teammates often distrust him, Wolverine is invaluable in rescuing the others and defeating their enemies, particularly in their conflict with the Hellfire Club; due to their influence, Jean transforms into the Dark Phoenix and apparently sacrifices herself, temporarily ending the love triangle involving her, Wolverine, and Cyclops. Wolverine becomes engaged to Mariko Yashida, a wealthy businesswoman whose father is head of the Clan Yashida criminal organization, and battles the Hand, a secret society of ninjas. However, she breaks off the engagement, under the influence of a member of the Hellfire Club. He battles Sabretooth, and discovers that he had multiple encounters with him that his traumatic amnesia concealed.
=== Lethal use === Pentobarbital has been publicized as a suicide method by assisted suicide advocacy groups, in particular Exit International. Around 2008, suicide tourists were traveling to Mexico in order to purchase pentobarbital from veterinary pharmacies, a means that is no longer possible owing to tighter controls. Around 2025, prosecutions for its illegal distribution to persons seeking to end their lives have occurred in Australia, France, and the United States.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.